When was Faron Pharmaceuticals founded?

Faron Pharmaceuticals was founded in 2007 and raised its 1st funding round 9 years after it was founded.

Where is Faron Pharmaceuticals located?

Faron Pharmaceuticals is headquartered in Turku, Finland.

Who is the current CEO of Faron Pharmaceuticals?

Markku Jalkanen of Faron Pharmaceuticals. They have also founded 1 company.

How many employees does Faron Pharmaceuticals have?

As of Jul 01, 2024, the latest employee count at Faron Pharmaceuticals is 50.

Is Faron Pharmaceuticals a funded company?

Faron Pharmaceuticals is a funded company, having raised an undisclosed amount across 17 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Sep 21, 2016.

When was the latest funding round of Faron Pharmaceuticals?

Faron Pharmaceuticals' latest funding was a €***** Post IPO round on Apr 03, 2025, with participation from 1 investor.

Where does Faron Pharmaceuticals rank among its competitors?

Faron Pharmaceuticals ranks 432nd amongst 3206 active competitors, of which 1096 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Faron Pharmaceuticals, which secured an undisclosed amount in Apr, 2025.

Who are the top competitors of Faron Pharmaceuticals?

Faron Pharmaceuticals' top competitors include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Among them, Faron Pharmaceuticals secured the most recent funding round in April, 2025.

Faron Pharmaceuticals - 2026 Company Profile, Team, Funding & Competitors

Company Details

Faron is a clinical-stage biopharmaceutical company developing drugs for acute organ traumas, vascular damage, and cancer immunotherapy. The pipeline consists of drug candidates (FP-1201-LYO and FP-1305) from two major Faron programmes – Traumakine® and Clevegen®, respectively. The indication of Traumakine (recombinant human IFN beta-1a) is acute respiratory distress syndrome (ARDS) & undergoing phase III clinical trials for the same. In addition, phase II trial is underway for the rupture of abdominal aorta aneurysm (RAAA). The second candidate, Clevegen® is a pre-clinical anti-Clever-1 antibody. It has the ability to switch immune suppression to immune activation in various conditions, This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology (TIET). The molecule has the potential indication for oncology, infectious disease, and vaccine development.

Website: faron.com
Email ID: *****@faron.com
Phone Number: +358 **********, +358 **********

Key Metrics

Founded Year

2007

Location

Turku, Finland

Stage

Public

Latest Funding Round

Post IPO, Apr 03, 2025, €*****

Investors

Heights Capital & 6 more

Ranked

432^nd among 3206 active competitors

Employee Count

50 as on Jul 01, 2024

Similar Companies

Regeneron Pharmaceuticals & 566 more

Exit Details

Public

View Faron Pharmaceuticals' full profile

Faron Pharmaceuticals is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
FARON USA LLC CIN: 824590360 , United States, Active	Dec 31, 1999	-	2 (As on Dec 31, 2023)	-
Faron Pharmaceuticals Oy CIN: 2068285-4 , Finland, Active	Oct 24, 2006	-	-	-
Faron Europe GmbH CIN: 1342478 , Switzerland, Active	Apr 25, 2023	-	-	-

Faron Pharmaceuticals got listed on Nov 17, 2015.

Click here to take a look at Faron Pharmaceuticals's IPO in detail

Faron Pharmaceuticals has raised funding over 17 rounds. Its first funding round was on Sep 21, 2016. Its latest funding round was a Post IPO round on Apr 03, 2025 for €*****. 1 investor participated in its latest round. Faron Pharmaceuticals has 6 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Faron Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 03, 2025	6268877	Post IPO	3987894	3316102	1844313	4663379
Feb 06, 2025	8019382	Post IPO	8926668	4804650	5422293	6947957
Aug 13, 2024	3127875	Grant (prize money)	5192079	9970417	1931726	Defense.gov

Access funding benchmarks and valuations. Sign up today!

View details of Faron Pharmaceuticals's funding rounds and investors

The founders of Faron Pharmaceuticals is Markku Jalkanen. Markku Jalkanen is the CEO of Faron Pharmaceuticals.

Here are the details of Faron Pharmaceuticals' key team members:

Markku Jalkanen: Founder & CEO of Faron Pharmaceuticals.

View details of Faron Pharmaceuticals's Founder profiles and Board Members

Faron Pharmaceuticals' employee count trend

Faron Pharmaceuticals has 50 employees as of Jul 24. Here is Faron Pharmaceuticals's employee count trend over the years:

Employee count trend for Faron Pharmaceuticals

Uncover Faron Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Faron Pharmaceuticals include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Here is the list of Top 10 competitors of Faron Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
6th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Tamburi Investment Partners, Vivo Capital ... & 4 others	73/100
7th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
8th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
9th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	72/100
10th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
432nd	Faron Pharmaceuticals 2007, Turku (Finland), Public	Clinical-stage developing immunotherapy for cancer, aorta aneurysm & ARDS	-	Heights Capital, Defense.gov & 5 others	54/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Faron Pharmaceuticals's competitors? Click here to see the top ones

Faron Pharmaceuticals has made no investments or acquisitions yet.

Here is the latest report on Faron Pharmaceuticals's sector:

Free

Oncology - Sector Report

Edition: October, 2025 (81 Pages)

View all reports related to Faron Pharmaceuticals

Media has covered Faron Pharmaceuticals for a total of 25 events in the last 1 year, 10 of them have been about company updates and 3 about partnerships.